Acromegaly Update

A thin top-tier week for acromegaly (one Pituitary paper plus a handful of solid next-tier studies, including a 2026 pipeline review), while rare disease news was dominated by positive Phase 3 readouts from Disc Medicine and Roivant, a second FDA look at Biohaven's ataxia drug, and early Huntington's data from Alnylam.

A thin week: no top-tier-journal acromegaly papers appeared, so Part A draws on the next tier (a radiomics model to predict somatostatin-analog response, a familial Carney-complex case, and bone proteomics), while the rare disease industry's big story is uniQure's four-year Huntington's gene therapy data, which showed a smaller, non-significant benefit and sent the stock down about 40%.

A quiet week for top-tier acromegaly literature (four papers, mostly real-world/consensus rather than trial data) paired with a livelier rare disease industry week — a first-ever positive pivotal trial in X-linked retinitis pigmentosa and a new FOP approval that goes head-to-head with Regeneron — while Marea's own MAR002 acromegaly program remains the clearest bridge between the two segments following its merger with Lisata.

This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.

It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-ever muscle-targeted SMA approval and a rough week for two RNA-based rare disease programs at Novartis.

It's a thin week for acromegaly-specific research — no top-tier-journal hits, so we're covering the best next-tier evidence on GH-axis physiology, octreotide drug delivery, and pituitary imaging AI — while rare disease industry news delivers a sharp one-two: Ionis just won the first-ever approval for Alexander disease, days after Ultragenyx's marquee Angelman syndrome drug flopped in Phase 3.

It's a quiet week for dedicated acromegaly research — no top-tier-journal hits, just a pasireotide cost-effectiveness review and a giant-adenoma case report — while the wider rare disease industry absorbed a surprise Phase 3 failure in the ATTR-CM heart drug market and a fresh round of White House drug-pricing deals touching major rare-disease manufacturers.

It's a quiet week for acromegaly-specific research — no top-tier trials, just a handful of diagnostic and mechanistic papers — while rare disease industry news brought two new FDA approvals (Priovant's Lisraya for dermatomyositis and Takeda/Protagonist's Mimrylo for polycythemia vera) that show regulators keep clearing novel mechanisms for small patient populations.

It was a quiet week for acromegaly-specific research — three observational studies refined how we monitor and support patients rather than changing treatment — while the wider rare disease industry saw two major FDA approvals and two sizable M&A deals land within days of each other.

It's an unusually rich week for acromegaly research — five new papers spanning a first-in-human antagonist trial and two large Swedish outcomes studies — while the rare disease industry saw a $1.3B rare-epilepsy buyout, a bankruptcy-auction gene therapy pickup, and a safety scare over a newly approved Prader-Willi drug.

It's a quiet week for acromegaly-specific trial data — the research side leans mechanistic and clinical-management, headlined by a novel long-acting GH receptor antagonist — while rare disease industry news brought a fresh Phase 2 win for Silence Therapeutics, an $800M Stargardt disease acquisition, a CRISPR safety insight from Intellia, and a Washington fight over whether orphan drugs get carved out of Medicare price pilots.

It's a quiet week for acromegaly-specific research — no trials, just incremental papers on AI-assisted detection, surgical outcomes, and pediatric gigantism — while the broader rare disease industry saw a gene-editing "gold rush" for a liver/lung disorder, a financing bet against two bigger rivals in Angelman syndrome, and a pulmonary hypertension partnership fall apart after a near-miss trial.

A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing startup inked a licensing deal and orphan drugmakers pushed back on Medicare price-pilot exposure.

A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.

It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.